Lege Artis Medicinae

[PLEIOTROPIC FUNCTIONS OF ERYTHROPOIETIN]

NAGY Judit, KISS István

DECEMBER 20, 2007

Lege Artis Medicinae - 2007;17(12)

[Erythropoietin produced by the foetal liver and the adult kidney is the major stimulator of erythropoiesis. Erythropoietin production is regulated by hypoxic activation of erythropoietin gene transcription. Recently, new sites of erythropoietin production have been found mainly in the central nervous system and in the cardiovascular system. These tissues have a paracrine and/or autocrine system of erythopoietin. The pleiotropic function of erythropoietin in these systems is tissue and cell protection by several mechanisms including inhibition of apoptosis, attenuation of ischaemic or reperfusion injury, anti-inflammatory and antioxidative effects. Furthermore, it promotes vascular recovery and enhances neoangiogenesis. In vivo and in vitro studies have proved that systemically administered human erythropoietin can also provide tissue protection. However, adverse effects of erythropoietin treatment such as hypertension, hyperviscosity and thrombosis may override the beneficial effect of systemic erythropoietin treatment. There are preliminary data that erythropoietin analogues, e.g., asyaloerythropoietin or carbamylated erythropoietin can provide tissue protection without stimulating erythropoiesis.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[The effects of oral rabeprazol and intravenous pantoprazol on intragastric pH. Comparison in healthy subjects]

NEMESÁNSZKY Elemér

Lege Artis Medicinae

[About the Homeland in the GP’s District]

CSAPÓ Gábor

Lege Artis Medicinae

[The effects of nebivolol therapy on respiratory function and quality of life]

BENCZÚR Béla

Lege Artis Medicinae

[Ophthalmologic Examination of the Homeless in Budapest]

SZALAI László

Lege Artis Medicinae

[RETROPERITONEAL LIPOSARCOMA]

NÉMETH Hajnalka, KOVÁCS Erzsébet, SÁPY Péter, PÁSZTOR Éva, DEZSŐ Balázs, SZŐLLŐSI Zoltán, PFLIEGLER György

[INTRODUCTION - Liposarcoma is a malignant soft tissue tumour, which represents less than 0.1% of all human cancers. Approximately 20% of liposarcomas arise in the retroperitoneum. Radical surgical excision is potentially curative, making it the first choice of treatment. For local tumour control palliative chemo- and/or radiotherapy can be used. CASE REPORT - A 28-year-old man with a history of weight loss, fatigue and abdominal tightness was diagnosed to have a giant dedifferentiated retroperitoneal liposarcoma, which showed aggressive growth and gave local recurrences. Multiple surgical excisions were performed, the first two times with curative, subsequently with palliative intent. To reduce the retroperitoneal tumour mass, several chemotherapeutic regimens were applied with complementary radiotherapy. As a result of the combinational therapy, tumour growth stopped temporarily, pressure pain subsided and the patient's quality of life was satisfactory. Finally, distant metastases developed in the bones of the right hip, in the lung and on the serous membranes and after 44 months of follow-up the patient died. CONCLUSION - It has been postulated that ifosfamide and doxorubicin based combined chemotherapy prevents or postpones the development of distant metastases. Considering the significant risk of local and distant recurrences, the use of ifosfamide-doxorubicin based combined chemotherapy is recommended in highgrade retroperitoneal liposarcoma, even following complete surgical excision.]

All articles in the issue

Related contents

Clinical Neuroscience

[HISTOCHEMISTRY OF THE EXTRACELLULAR MATRIX IN THE SNAIL CENTRAL NERVOUS SYSTEM]

SERFŐZŐ Zoltán, ELEKES Károly

[Even tough the central nervous system (CNS) of gastropods has long been used as a model for studying different neuronal networks underlying behaviors, there is only little information on the molecular components of the extracellular matrix (ECM) of the nervous tissue. Therefore, the aim of the present study was to identify some of the ECM molecules by acid-base histochemistry. Staining with alcian blue at strong acidic pH, and with acridine orange at different pH and salt concentrations was carried out on cryostat sections taken from CNS preparations of adult specimens of the terrestrial snail, Helix pomatia, and the aquatic species, Lymnaea stagnalis, in order to visualize mild (carboxyl) and strong (sulphate) acidic groups, which are characteristic for different glucosaminoglycans. According to our findings, sulphated proteoglycans were abundant in the periganglionic sheath of both species, and they also occurred in the neuropil of Helix, whereas they were absent in Lymnaea. The interperikaryonal space contained mainly carboxyl residues, which might refer to the presence of hyaluronic acid. It is concluded that the ECM of the snail CNS, similarly to that in vertebrates, is partly composed of polymer macromolecules of different chemical properties. It is suggested that adaptation to environmental conditions and/or altered neuronal plasticity are responsible for the differences found in chemical characters of the ECM molecules between the two snail species.]

Lege Artis Medicinae

[RENAL ANAEMIA AND CURRENT ISSUES ON ERYTHROPOIETIN THERAPY]

ZAKAR Gábor

[Recombinant human erythropoietin has been used for more than 20 years for the treatment of renal anaemia, with epoetin-alfa and -beta representing the common traditional preparations. By the modification of the molecule’s carbohydrate moiety or structure a longer duration of erythropoietin receptor stimulation was achieved. The administration of these new molecules (darbepoetin, C.E.R.A.) once or twice a month is also sufficient to achieve serum haemoglobin target levels, making the treatment safer and more comfortable both for the patients and the personnel. These recently developed synthetic erythropoietin receptor stimulating molecules, along with recombinant human erythropoietin, are together called “Erythropoiesis Stimulating Agents”. In haemodialysed patients the intravenous route is preferred, but the subcutaneous administration can substantially reduce dose requirements. In praedialysed, transplanted or peritoneally dialysed patients, erythropoiesis stimulating agents should preferably be given subcutaneously both for economic and practical reasons. There are ongoing clinical trials with erythropoiesis stimulating molecules that can be administered by inhalation or per os. Current evidence suggests that the serum haemoglobin level should preferably not exceed 12 g/dl with the use of erythropoiesis stimulating agents. No cardiovascular protective effect of higher serum haemoglobin levels was demonstrated in two large clinical trials. Further well-designed studies are necessary to set evidence-based haemoglobin targets for erythropoiesis stimulating treatment. Arguments for a more widespread use of agents with extended duration include medical, financial and patient satisfaction reasons. The release of new erythropoiesis stimulating agents may further simplify the treatment of renal anaemia.]

Clinical Neuroscience

[Fingolimod therapy in multiple sclerosis - the issue of the pathomechanism]

TAR Lilla, VÉCSEI László

[Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system with neurodegenerative chararacteristics. The newly discovered per os administrable drug fingolimod (FTY720) has a different mechanism of action than the current disease-modifying therapies. In vivo the drug binds to four out of the five sphingosine-1-phosphate receptors after phosphorylation. Fingolimod-phosphate (FTY720-P) causes internalization and degradation of the sphingosine-1-phosphate receptors in the membrane of lymphocytes thus in contrast to sphingosine-1-phosphate it acts like a functional antagonist. In experimental autoimmune encephalomyelitis - an animal model of multiple sclerosis - fingolimod blocks the sphingosine-1-phosphate gradient controlled lymphocyte egress from the lymph nodes and therefore reduces the peripheral lymphocyte count especially the encephalitogenic Th17 subset is reduced. Modulation of the sinus lining and blood-brainbarrier constructing endothelial cells also contributes to the complex mechanism of action. Additionally due to its liphohilic nature fingolimod is able to penetrate the blood brain barrier thus, beside its peripheral effects the drug can probably modulate the cells of the central nervous system directly. Presumably it can reduce neurodegeneration caused by astrogliosis through modification of astrocyte and oligodendrocyte activity. The results of current clinical studies are holding out with bright prospective in the aspect of either the favourable effects or the well tolerated side effects.]

Hypertension and nephrology

[Biosimilar erythropoesis stimulating agents - from registration to clinical practice]

KISS István

[The original patent drugs appear immediately on expiry of all rights in generic and biosimilar drugs in the pharmaceutical market, favorable supply option which helps in the rational management of medicines, mainly for generic drugs cheaper to allow more patient care. Of course, this is a well-organized legal and regulatory framework, thoughtful strategy can be successful in every respect. In another non-identical molecular structure biosimilar drugs in different immunogenicity of knowledge and risk is not defined in clinical practice and therefore the risk is still underestimated and not well regulated in the world, and increasing the number reported is the antibody formation case of a biosimilar erythropioetin also. The immunogenicity of original biological and of biosimilar drugs in identifying, defining a prominent role in the post-marketing surveillance, pharmacovigilance, and the special methods of control of immunogenicity. The original and the biosimilar medicines interchangeability, marketability of the assets relating to the regulations are not uniform in Europe or the European registration scheme is an important new biosimilar medicinal products, is that the medicinal product, the documentation is not expected to be accompanied by a risk management plan, as well as action to ensure the safety (pharmacovigilance) as part of the collection and reporting of adverse reactions to the official. It is important that the professional management of renal anemia guidelines - the practice of nephrology erythropoietin therapy - clearly define the biological medicines (originator and biosimilar erythropoietin) application requirements and suggestions. Consequently, this summary wants to draw attention to the therapeutic potential of biosimilar drugs, generic drugs to distinguish between explicit and the potential risks and the need to reduce the risks of professional and health policy decisions.]

Clinical Neuroscience

[EFFECTS OF KETAMINE ON THE DEVELOPING CENTRAL NERVOUS SYSTEM]

VUTSKITS László, GASCON Eduardo, KISS Zoltán József

[Ketamine is a widely used drug in pediatric anesthesia practice, acting primarily through the blockade of the Nmethyl- D-aspartate (NMDA) type of glutamate receptors. A growing body of laboratory evidence, accumulated during the past few years, suggests that this drug could have potential adverse effects on the developing central nervous system. The goal of this short review is to give a brief synopsis of experimental work indicating ketamine-induced developmental neurotoxicity as well as to discuss potential limitations concerning extrapolation of these studies to clinical practice.]